Multiple Myeloma (MM) is a disease of plasma cells in which expanded clones of malignant plasma cells will take over the bone marrow space. The typical clinical symptoms of MM include bone lesions, hypercalcemia, anemia, immune suppression, and multiple organ failure. MM is one of the second most common hematological malignancies with complicated genetic backgrounds.
Advances in the treatment including autologous stem cell transplantation and the administration of therapeutic drugs (proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and histone deacetylase inhibitors) have significantly improved the disease free survival of MM patients. However, MM remains incurable for relapsed patients. Thus, there is an urgent need to identify a novel target for MM therapy, especially for relapsed and drug resistant patients.
In this research special topic, we encourage the submission of original research and review articles related to the topic but are not limited to, the following subjects:
1. Genetic screening or small molecular screening to identify novel targets for MM treatment.
2. Identify novel mechanisms of drug resistance and relapsed MM.
3. Characterize the functions of novel targets for MM treatment.
4. Develop a novel combined therapy for MM treatment, focusing on drug resistance and relapsed MM.
5. Animal models of MM to develop novel therapies and identify molecular targets.
6. Using bioinformatics tools to identify MM signatures or potential targets.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section.
Multiple Myeloma (MM) is a disease of plasma cells in which expanded clones of malignant plasma cells will take over the bone marrow space. The typical clinical symptoms of MM include bone lesions, hypercalcemia, anemia, immune suppression, and multiple organ failure. MM is one of the second most common hematological malignancies with complicated genetic backgrounds.
Advances in the treatment including autologous stem cell transplantation and the administration of therapeutic drugs (proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and histone deacetylase inhibitors) have significantly improved the disease free survival of MM patients. However, MM remains incurable for relapsed patients. Thus, there is an urgent need to identify a novel target for MM therapy, especially for relapsed and drug resistant patients.
In this research special topic, we encourage the submission of original research and review articles related to the topic but are not limited to, the following subjects:
1. Genetic screening or small molecular screening to identify novel targets for MM treatment.
2. Identify novel mechanisms of drug resistance and relapsed MM.
3. Characterize the functions of novel targets for MM treatment.
4. Develop a novel combined therapy for MM treatment, focusing on drug resistance and relapsed MM.
5. Animal models of MM to develop novel therapies and identify molecular targets.
6. Using bioinformatics tools to identify MM signatures or potential targets.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section.
